Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03142334 2026-03-10

KEYNOTE-564

Phase 3 Completed

994 enrolled 10 charts 1 FDA

Phase 2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Phase 2 Suspended

75 enrolled

Carcinoma, Renal Cell

NCT07218380 2026-03-06

FORAGER-2

Phase 3 Recruiting

450 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06661720 2026-03-04

STRIKE

Phase 3 Recruiting

1,040 enrolled

Carcinoma, Renal Cell

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04104893 2026-02-27

CHOMP

Phase 2 Active not recruiting

40 enrolled

Phase 3 Active not recruiting

Turcot syndrome, Prostatic Neoplasms

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

47 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06483334 2026-02-18

MK-3475-04C

Phase 1/2 Active not recruiting

38 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT07166601 2026-02-18

TITER

77 enrolled

GenitourinaryThoracic

Medullary cystic kidney disease 1, Carcinoma, Non-Small-Cell Lung

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT05155033 2026-02-17

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

DermatologicGenitourinary

78 enrolled

Carcinoma, Renal Cell, Melanoma

NCT05581004 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2/3 Recruiting

956 enrolled

Urinary Bladder Neoplasms

NCT07160335 2026-02-13

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

DermatologicGenitourinaryThoracic

174 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04626479 2026-02-12

MK-3475-03A

Phase 1/2 Active not recruiting

400 enrolled

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05805501 2026-02-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

199 enrolled

Carcinoma, Renal Cell

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Phase 1 Active not recruiting

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT05479812 2026-02-09

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

150 enrolled

DermatologicGenitourinaryThoracic

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT05787587 2026-02-09

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

216 enrolled

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06716853 2026-02-09

TEM-GU

Phase 1/2 Terminated

10 enrolled

Carcinoma, Renal Cell

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

21 enrolled